These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37226898)

  • 41. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
    Bowden NA
    Cancer Lett; 2014 May; 346(2):163-71. PubMed ID: 24462818
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
    Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
    Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
    Ledermann JA; Gabra H; Jayson GC; Spanswick VJ; Rustin GJ; Jitlal M; James LE; Hartley JA
    Clin Cancer Res; 2010 Oct; 16(19):4899-905. PubMed ID: 20719935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
    Wong B; Bergeron A; Maznyi G; Ng K; Jirovec A; Birdi HK; Serrano D; Spinelli M; Thomson M; Taha Z; Alwithenani A; Chen A; Lorimer I; Vanderhyden B; Arulanandam R; Diallo JS
    Mol Ther; 2023 Nov; 31(11):3176-3192. PubMed ID: 37766429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Jakobsen A
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cystic presentation of a renal medullary carcinoma in a young woman.
    Levi Sandri GB; Spoletini G; Lai Q; Mennini G; Rossi M
    Urologia; 2015; 82(2):124-6. PubMed ID: 25451881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.
    Picco G; Petti C; Sassi F; Grillone K; Migliardi G; Rossi T; Isella C; Di Nicolantonio F; Sarotto I; Sapino A; Bardelli A; Trusolino L; Bertotti A; Medico E
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27771609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.
    Msaouel P; Malouf GG; Su X; Yao H; Tripathi DN; Soeung M; Gao J; Rao P; Coarfa C; Creighton CJ; Bertocchio JP; Kunnimalaiyaan S; Multani AS; Blando J; He R; Shapiro DD; Perelli L; Srinivasan S; Carbone F; Pilié PG; Karki M; Seervai RNH; Vokshi BH; Lopez-Terrada D; Cheng EH; Tang X; Lu W; Wistuba II; Thompson TC; Davidson I; Giuliani V; Schlacher K; Carugo A; Heffernan TP; Sharma P; Karam JA; Wood CG; Walker CL; Genovese G; Tannir NM
    Cancer Cell; 2020 May; 37(5):720-734.e13. PubMed ID: 32359397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
    Msaouel P; Tannir NM; Walker CL
    Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
    Carter SA; Walker AN
    J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
    Xie D; Yin RT; Li KM; Xiao P; Tong LX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):606-11. PubMed ID: 25286685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
    Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma.
    Burkett WC; Zhao Z; Newton MA; Sun W; Deng B; Secord AA; Zhou C; Bae-Jump V
    Ann Med; 2023 Dec; 55(1):603-614. PubMed ID: 36773034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent Advances in Renal Medullary Carcinoma.
    Su Y; Hong AL
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
    Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
    J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
    Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
    PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
    Westfall SD; Skinner MK
    Mol Cancer Ther; 2005 Nov; 4(11):1764-71. PubMed ID: 16275998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.